Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.81 |
| ▸ | BACE1 | P56817 | 9/20 | 0.81 |
| ▸ | F3 | P13726 | 2/20 | 0.62 |
| ▸ | FOS | P01100 | 2/20 | 0.57 |
| ▸ | JUN | P05412 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10021722 | 0.90 | F3 (0.77) | GSK3BBACE1F3THRBATM | |
| SCHEMBL610787 | 0.90 | GSK3B (1.00) | GSK3BBACE1F3FOSJUN | |
| SCHEMBL610786 | 0.90 | GSK3B (1.00) | GSK3BBACE1F3FOSJUN | |
| SCHEMBL18699288 | 0.85 | GSK3B (0.91) | GSK3BBACE1F3FOSJUN | |
| SCHEMBL18513427 | 0.84 | GSK3B (0.88) | GSK3BBACE1F3FOSJUN | |
| SCHEMBL12572843 | 0.82 | GSK3B (0.81) | GSK3BBACE1F3THRBATM | |
| SCHEMBL13358511 | 0.82 | GSK3B (0.69) | GSK3BBACE1F3FOSJUN | |
| SCHEMBL16576810 | 0.81 | NPC1 (0.73) | GSK3BBACE1F3THRBATM | |
| SCHEMBL25191845 | 0.80 | F3 (0.79) | F3NPC1RAB9A | |
| SCHEMBL12334511 | 0.80 | F3 (0.79) | F3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-03-22 | — | — | US | disclosed |
| US-9907786-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-03-06 | — | — | US | disclosed |
| US-20170216222-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-08-03 | — | — | US | disclosed |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | disclosed |
| US-20170105976-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | Ions Pharmaceutical S.à r.I. (LU) | 2017-04-20 | — | — | US | disclosed |
| US-20170042867-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-20170042866-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-9402834-B2 | Human therapeutic agents | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-08-02 | — | — | US | disclosed |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106721-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
| US-20160106722-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | GSK3B 2812/4885BACE1 750/4885F3 4781/4885 |
| US-20170216222-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | GSK3B 462/4885BACE1 500/4885F3 4252/4885 |
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | GSK3B 462/4885BACE1 500/4885F3 4252/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | GSK3B 708/4885BACE1 575/4885F3 3876/4885 |
| US-20170105976-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | GSK3B 462/4885BACE1 500/4885F3 4252/4885 |
| US-20170042867-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | GSK3B 462/4885BACE1 500/4885F3 4252/4885 |
| US-20170042866-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | GSK3B 462/4885BACE1 500/4885F3 4252/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | GSK3B 2812/4885BACE1 750/4885F3 4781/4885 |
| US-20160106722-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | GSK3B 2563/4885BACE1 1295/4885F3 4264/4885 |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | GSK3B 462/4885BACE1 500/4885F3 4252/4885 |
| US-20160106721-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | GSK3B 2563/4885BACE1 1295/4885F3 4264/4885 |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | GSK3B 2563/4885BACE1 1295/4885F3 4264/4885 |
| US-20120040976-A1 | SMALL MOLECULE IMMUNOMODULATORS FOR ALZHEIMER'S DISEASE | L1CAM, LY96, GMFG | GSK3B 3394/4885BACE1 435/4885F3 4825/4885 |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | GSK3B 2563/4885BACE1 1295/4885F3 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.